VT-105
Universal Influenza A
Phase 1Active
Key Facts
About Versatope Therapeutics
Versatope Therapeutics is developing a novel vaccine and therapeutic delivery platform using engineered nano-vesicles derived from probiotics, known as Recombinant Extracellular Transport Vesicles (RET-Vs). The company's lead asset, VT-105, is a universal influenza A vaccine candidate that has received IND allowance and is poised for clinical studies. The platform's versatility also allows for applications in other infectious diseases, cancer, and allergy, positioning Versatope to address significant unmet needs in immunotherapy.
View full company profile